CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Standard PlasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug225 Convalescent Plasma Wiki 0.35

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D004630 Emergencies NIH 0.35

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Double-Blind, Phase 2 Study Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Placebo in Emergency Room Patients

This study will evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma (convalescent plasma) versus control (standard plasma) in patients with COVID-19 respiratory symptoms. This study will recruit patients who present for clinical evaluation in the emergency department (ED) but who do not require hospital admission. Disease progression due to COVID-19 will be assessed, which may include changes in symptom severity, return visit to the ED, or hospital admission.

NCT04355767 COVID-19 Biological: Convalescent Plasma Biological: Standard Plasma
MeSH:Emergencies

Primary Outcomes

Description: Progression of disease is defined as any of the following: Patient admitted to the hospital Patient seen in the emergency room (return visit after visit when enrollment takes place) Patient reports increased symptoms of 2 levels on the COVID Outpatient Ordinal Outcomes Scale over a 24 hour period Patient reports increased symptoms of 1 level on the COVID Outpatient Ordinal Outcomes Scale observed for a 48 hour period. COVID Outpatient Ordinal Outcomes Scale: Patient requires care in the hospital Patient requires care in the ED or urgent care Patient at home with symptoms rates as moderate (defined as fever, shortness of breath, abdominal pain) Patient at home with symptoms rated as mild (defined as afebrile, constitutional symptoms (flu-like illness) without shortness of breath) Patient in their usual state of health

Measure: Time to disease progression

Time: 15 days

Secondary Outcomes

Description: Categorical change in symptom severity rated on the COVID Outpatient Ordinal Outcomes Scale: Patient requires care in the hospital Patient requires care in the ED or urgent care Patient at home with symptoms rates as moderate (defined as fever, shortness of breath, abdominal pain) Patient at home with symptoms rated as mild (defined as afebrile, constitutional symptoms (flu-like illness) without shortness of breath) Patient in their usual state of health

Measure: Change in symptom severity over time

Time: 15 days


No related HPO nodes (Using clinical trials)